NEW YORK, Dec 13 - Incyte Genomics said Wednesday it has formed two genomic research partnerships with leading academic institutions to study common diseases.
The company is partnering with the University of California San Francisco to study prostate cancer, and with CARIM, the Maastricht Cardiovascular Research Institute in the Netherlands to study cardiovascular disease.
The UCSF collaboration “is consistent with our strategy to provide in-depth research for significant therapeutic areas to the life science community,” said Incyte CEO Roy A. Whitfield in a statement announcing this agreement.
Intellectual property resulting from both collaborations will be jointly owned by the respective institutes and Incyte, and will be available for licensing through Incyte.
In the UCSF agreement, the university will provide both normal and diseased prostate samples to Incyte for use in expression studies jointly developed by scientists at UCSF and Incyte. CARIM will also provide clinical and experimental samples to Incyte and will collaborate with Incyte on gene expression experiments to study the role genes play in the prevention, diagnosis, and treatment of cardiovascular disease.
Incyte will incorporate the data resulting from both collaborations into its LifeExpress database, which integrates gene and protein expression data. According to the company, LifeExpress allows researchers to correlate gene and protein behavior in both diseased and normal tissues, prioritize potential drug targets, and more quickly assess the efficacy and toxicity of compounds.
As part of their agreement, researchers at CARIM will gain access to the LifeExpress database as well as Incyte's LifeSeq Gold gene sequence database.
The two new collaborations are part of Incyte’s strategy to build partnerships with academic institutions. The company has entered into similar alliances with Baylor College of Medicine, the Roy Castle International Centre for Lung Cancer Research and the Huntsman Cancer Institute at the University of Utah.
Incyte was not immediately available for comment on further terms of the partnerships.